Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Comprehensive behavioral analysis of tryptophan 2,3-dioxygenase (Tdo2) knockout mice.

Hattori S, Takao K, Funakoshi H, Miyakawa T.

Neuropsychopharmacol Rep. 2018 Jun;38(2):52-60. doi: 10.1002/npr2.12006. Epub 2018 Mar 15.

2.

Immature-like molecular expression patterns in the hippocampus of a mouse model of dementia with Lewy body-linked mutant β-synuclein.

Hagihara H, Fujita M, Umemori J, Hashimoto M, Miyakawa T.

Mol Brain. 2018 Jul 6;11(1):38. doi: 10.1186/s13041-018-0378-3.

3.

The kynurenine pathway in schizophrenia and bipolar disorder.

Erhardt S, Schwieler L, Imbeault S, Engberg G.

Neuropharmacology. 2017 Jan;112(Pt B):297-306. doi: 10.1016/j.neuropharm.2016.05.020. Epub 2016 May 28. Review.

PMID:
27245499
4.

Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder.

Miller CL, Murakami P, Ruczinski I, Ross RG, Sinkus M, Sullivan B, Leonard S.

Schizophr Res. 2009 Sep;113(2-3):259-67. doi: 10.1016/j.schres.2009.05.014. Epub 2009 Jun 6.

5.

Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder.

Miller CL, Llenos IC, Cwik M, Walkup J, Weis S.

Neurochem Int. 2008 May;52(6):1297-303. doi: 10.1016/j.neuint.2008.01.013. Epub 2008 Feb 2.

PMID:
18328600
6.
7.

Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia.

Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S.

Neurobiol Dis. 2004 Apr;15(3):618-29.

PMID:
15056470

Supplemental Content

Loading ...
Support Center